Another bio tech What was I thinking?
"The Company’s cash position of $23.6 million at 31 December 2020 combined with significant accrued research and development rebate credits means Recce Pharmaceuticals is sufficiently funded to execute its development milestones through the 2021 financial year. " interim report 31 dec 2020
"Recce Clinical Pipeline Update " says "Full data" end Q4, 2021 and 2022 and mid-2022 for results add in the wild card Covid data anticipated Q4 2021giving several near term re-ratings.
In for the results pipeline for me . I may need to change my user name to BIOTECH tragicThe little dip today made me jump.
Have a great day all
Another bio tech What was I thinking?"The Company’s cash...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.080(21.9%) |
Mkt cap ! $128.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 44.5¢ | 37.5¢ | $191.2K | 477.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12222 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 10976 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |